Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Federal Trade Commission
McKinsey
Express Scripts
Cerilliant
Harvard Business School
Julphar
Farmers Insurance
Queensland Health

Generated: May 26, 2018

DrugPatentWatch Database Preview

BAYER Company Profile

« Back to Dashboard

Summary for BAYER
International Patents:1512
US Patents:49
Tradenames:110
Ingredients:75
NDAs:127
Patent Litigation for BAYER: See patent lawsuits for BAYER

Drugs and US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Pharms BAYCOL cerivastatin sodium TABLET;ORAL 020740-003 Jun 26, 1997 DISCN No No ➤ Sign Up ➤ Sign Up
Bayer Pharms AZLIN azlocillin sodium INJECTABLE;INJECTION 062388-002 Sep 8, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Bayer Healthcare Llc MYCELEX-7 clotrimazole CREAM;VAGINAL 018230-002 Dec 26, 1991 DISCN No No ➤ Sign Up ➤ Sign Up
Bayer Pharms MEZLIN mezlocillin sodium monohydrate INJECTABLE;INJECTION 062697-001 Jan 22, 1987 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for BAYER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer Hlthcare REFLUDAN lepirudin recombinant INJECTABLE;INJECTION 020807-001 Mar 6, 1998 5,180,668 ➤ Sign Up
Bayer Pharms BAYCOL cerivastatin sodium TABLET;ORAL 020740-001 Jun 26, 1997 5,006,530 ➤ Sign Up
Bayer Pharms ADALAT nifedipine CAPSULE;ORAL 019478-002 Sep 17, 1986 3,784,684 ➤ Sign Up
Bayer Hlthcare CLIMARA PRO estradiol; levonorgestrel FILM, EXTENDED RELEASE;TRANSDERMAL 021258-001 Nov 21, 2003 5,676,968 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BAYER drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 3 mg/0.03 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-09-28
➤ Subscribe Tablets 25 mg, 50 mg and 100 mg ➤ Subscribe 2005-03-22
➤ Subscribe Injection 1.6 mg/mL ➤ Subscribe 2014-02-07
➤ Subscribe Tablets 3 mg/0.02 mg ➤ Subscribe 2006-09-29
➤ Subscribe Tablets 0.25 mg/0.5 mg ➤ Subscribe 2015-01-08
➤ Subscribe Transdermal System 0.05 mg/day and 0.1 mg/day ➤ Subscribe 2005-09-12
➤ Subscribe Topical Foam 15% ➤ Subscribe 2017-09-14
➤ Subscribe Tablets 5 mg ad 10 mg ➤ Subscribe 2009-07-10
➤ Subscribe Oral Suspension 250 mg/5 mL and 500 mg/ 5 mL ➤ Subscribe 2009-10-16
➤ Subscribe Tablets 3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg ➤ Subscribe 2010-10-22
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2011-11-21
➤ Subscribe Gel 15% ➤ Subscribe 2012-07-27
➤ Subscribe Tablets 3 mg/0.02 mg/0.451 mg and 0.451 mg ➤ Subscribe 2012-11-13
➤ Subscribe Tablets 0.5 mg/1 mg ➤ Subscribe 2007-12-26
➤ Subscribe Tablets 200 mg ➤ Subscribe 2014-02-28
➤ Subscribe Tablets 3 mg/0.03 mg ➤ Subscribe 2005-01-07
➤ Subscribe Tablets 40 mg ➤ Subscribe 2016-09-27
➤ Subscribe Tablets 20 mg ➤ Subscribe 2009-03-05
➤ Subscribe Tablets 0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg ➤ Subscribe 2017-10-10
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2009-09-04
➤ Subscribe Capsules 20 mg/1100 mg ➤ Subscribe 2010-04-20
➤ Subscribe Gel 0.05% ➤ Subscribe 2010-12-01
➤ Subscribe Orally Disintegrating Tablets 10 mg ➤ Subscribe 2011-12-22
Premature patent expirations for BAYER

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for BAYER

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,119,150 Non-flammable insecticide composition and uses thereof ➤ Sign Up
9,682,021 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses ➤ Sign Up
9,492,412 Penetrating pharmaceutical foam ➤ Sign Up
9,452,082 Inserter ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for BAYER Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0044 Belgium ➤ Sign Up PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615
/2006 Austria ➤ Sign Up PRODUCT NAME: SORAFENIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE HIERVON; REGISTRATION NO/DATE: EU/1/06/342/001 20060719
C/GB97/077 United Kingdom ➤ Sign Up PRODUCT NAME: LEPIRUDIN, OPTIONALLY IN THE FORM OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/97/035/001 19970313; UK EU/1/97/035/002 19970313
00221 Netherlands ➤ Sign Up PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Chubb
Harvard Business School
Baxter
Covington
Cerilliant
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.